Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Dalcetrapib · JTT-705, RO-4607381

Small molecule · Inhibitor of cholesteryl ester transfer protein (CETP) · developed by Hoffmann-La Roche

Phase 3 Most advanced trial (none active)
1 Registered trials

What is Dalcetrapib?

Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that increases serum HDL-cholesterol and decreases serum LDL-cholesterol levels. It raises functional HDL through a mechanism distinct from other CETP inhibitors. It is studied in acute coronary syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
JTT-705, RO-4607381
Drug type
Small molecule
Targets
cholesteryl ester transfer protein (CETP)
Mechanism
Inhibitor of cholesteryl ester transfer protein (CETP)
Pathways
HDL metabolism, LDL metabolism
Therapy area
Cardiovascular
Developer
Hoffmann-La Roche
In trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
3D050LIQ3H

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02525939 Phase 3 Acute Coronary Syndrome Completed MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Coronary Syndrome

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.